JP6478908B2 - 熱ショックタンパク質（ＨＳＰ）９０−βを調節することによる代謝症候群の治療方法 - Google Patents

熱ショックタンパク質（ＨＳＰ）９０−βを調節することによる代謝症候群の治療方法 Download PDF

Info

Publication number
JP6478908B2
JP6478908B2 JP2015514227A JP2015514227A JP6478908B2 JP 6478908 B2 JP6478908 B2 JP 6478908B2 JP 2015514227 A JP2015514227 A JP 2015514227A JP 2015514227 A JP2015514227 A JP 2015514227A JP 6478908 B2 JP6478908 B2 JP 6478908B2
Authority
JP
Japan
Prior art keywords
metabolic syndrome
hsp90β
pharmaceutical composition
insulin
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015514227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015520170A5 (enExample
JP2015520170A (ja
Inventor
ナレイン，ニーブン，ラジン
サランガラジャン，ランガプラサド
ビッシュヌダス，ビベック，ケー．
ジン，エンシュアン
Original Assignee
バーグ エルエルシー
バーグ エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バーグ エルエルシー, バーグ エルエルシー filed Critical バーグ エルエルシー
Publication of JP2015520170A publication Critical patent/JP2015520170A/ja
Publication of JP2015520170A5 publication Critical patent/JP2015520170A5/ja
Application granted granted Critical
Publication of JP6478908B2 publication Critical patent/JP6478908B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
JP2015514227A 2012-05-25 2013-05-24 熱ショックタンパク質（ＨＳＰ）９０−βを調節することによる代謝症候群の治療方法 Expired - Fee Related JP6478908B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261652023P 2012-05-25 2012-05-25
US61/652,023 2012-05-25
PCT/US2013/042692 WO2013177535A2 (en) 2012-05-25 2013-05-24 Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta

Publications (3)

Publication Number Publication Date
JP2015520170A JP2015520170A (ja) 2015-07-16
JP2015520170A5 JP2015520170A5 (enExample) 2016-07-14
JP6478908B2 true JP6478908B2 (ja) 2019-03-06

Family

ID=49624539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015514227A Expired - Fee Related JP6478908B2 (ja) 2012-05-25 2013-05-24 熱ショックタンパク質（ＨＳＰ）９０−βを調節することによる代謝症候群の治療方法

Country Status (15)

Country Link
US (2) US9533002B2 (enExample)
EP (1) EP2854865B1 (enExample)
JP (1) JP6478908B2 (enExample)
KR (1) KR20150010793A (enExample)
CN (1) CN104812898B (enExample)
AU (1) AU2013266086B2 (enExample)
BR (1) BR112014029301A2 (enExample)
CA (1) CA2874676A1 (enExample)
EA (1) EA201492184A1 (enExample)
HK (1) HK1209035A1 (enExample)
IL (1) IL235910A0 (enExample)
MX (1) MX2014014188A (enExample)
NZ (1) NZ702169A (enExample)
SG (1) SG11201407775WA (enExample)
WO (1) WO2013177535A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1209035A1 (en) * 2012-05-25 2016-03-24 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
CN111529534A (zh) 2012-09-27 2020-08-14 儿童医学中心公司 用于治疗肥胖症的化合物和其使用方法
CN117357538A (zh) * 2014-03-26 2024-01-09 儿童医学中心公司 用于治疗肥胖症的雷公藤红素和衍生物
EP3152307A4 (en) 2014-06-06 2018-05-02 Berg LLC Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
JP6779867B2 (ja) 2014-06-13 2020-11-04 ユマ セラピューティクス，インコーポレーテッド ピリミジン化合物およびその使用方法
WO2016149575A1 (en) * 2015-03-19 2016-09-22 Old Dominion University Synergistic regulated cell death induction with hsp90 inhibitors and nanosecond pulsed electric fields
JP7034078B2 (ja) * 2015-10-23 2022-03-11 イーアールエックス ファーマシューティカルズ インコーポレイテッド セラストロールの類似体
CN105920018B (zh) * 2016-06-15 2019-01-11 上海市内分泌代谢病研究所 雷公藤红素联合小檗碱制备治疗肥胖药物的用途
CN107543929A (zh) * 2016-06-23 2018-01-05 中国医学科学院肿瘤医院 基于蛋白标志物hsp90ab1诊断肺癌患者的试剂盒
CN107028953A (zh) * 2017-03-27 2017-08-11 北京大学 一种交感神经活性的刺激剂
CA3061185A1 (en) * 2017-04-24 2018-11-01 Samus Therapeutics, Inc. Hsp90 inhibitor oral formulations and related methods
WO2018235251A1 (ja) * 2017-06-23 2018-12-27 株式会社ニコン 解析装置、解析プログラム及び解析方法
CN112156188A (zh) * 2020-11-10 2021-01-01 上海交通大学医学院附属瑞金医院 Hsp90作为制备预防与治疗类固醇糖尿病药物的用途
CN113332308A (zh) * 2021-02-22 2021-09-03 广东省妇幼保健院 调控hsp90 b1表达量的制剂在制备预防或治疗多囊卵巢综合征药物中的应用
CN113160983A (zh) * 2021-04-09 2021-07-23 南京医科大学附属逸夫医院 一种代谢相关脂肪性肝病临床预测模型

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078375B1 (en) 1996-10-25 2006-07-18 Peter Mose Larsen Diabetes-mediating proteins and therapeutic uses thereof
US20040048256A1 (en) * 2001-09-07 2004-03-11 Agee Michele L. Novel proteins and nucleic acids encoding same
WO2004033657A2 (en) 2002-10-07 2004-04-22 Antigenics, Inc. Heat shock protein binding fragments of cd91, and uses thereof
WO2004072080A1 (en) 2003-02-10 2004-08-26 Cellular Genomics, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of hsp90 complex activity
GB0309637D0 (en) 2003-04-28 2003-06-04 Cancer Rec Tech Ltd Pyrazole compounds
WO2005021552A1 (en) 2003-08-29 2005-03-10 Vernalis (Cambridge) Ltd Pyrimidothiophene compounds
WO2005115431A2 (en) 2004-05-24 2005-12-08 Adonia Papathanassiu Methods for inhibiting proteasome and heat shock protein 90
WO2006020269A2 (en) 2004-07-19 2006-02-23 University Of Rochester Biomarkers of neurodegenerative disease
US20060094682A1 (en) 2004-10-29 2006-05-04 Odyssey Thera, Inc. Kinase inhibitors for the treatment of diabetes and obesity
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
FR2885904B1 (fr) 2005-05-19 2007-07-06 Aventis Pharma Sa Nouveaux derives du fluorene, compositions les contenant et utilisation
WO2007022042A2 (en) 2005-08-11 2007-02-22 Novartis Ag Combinations comrising a protein kinase inhibitor being a pyrimidylaminobξnzamide compound and a hsp90 inhibitor such as 17-aag
US20070207950A1 (en) 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
WO2007077042A1 (en) 2006-01-06 2007-07-12 Topotarget Switzerland Sa New method for the treatment of gout or pseudogout
US8658633B2 (en) 2006-02-16 2014-02-25 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
US20100015126A1 (en) 2006-03-17 2010-01-21 Martijn Frans Ben Gerard Gebbink Methods of Binding of Cross-Beta Structures By Chaperones
WO2007137237A2 (en) 2006-05-19 2007-11-29 The Scripps Research Institute Treatment of protein misfolding
US8318790B2 (en) 2006-05-25 2012-11-27 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
CA2661436A1 (en) 2006-08-24 2008-02-28 Serenex, Inc. Isoquinoline, quinazoline and phthalazine derivatives
WO2008024974A1 (en) 2006-08-24 2008-02-28 Serenex, Inc. Pyrimidine and pyrazine derivatives
US9730912B2 (en) 2006-10-12 2017-08-15 Astex Therapeutics Limited Pharmaceutical compounds
GB0620259D0 (en) * 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
US8277807B2 (en) 2006-10-12 2012-10-02 Astex Therapeutics Limited Pharmaceutical combinations
GB0622084D0 (en) 2006-11-06 2006-12-13 Chroma Therapeutics Ltd Inhibitors of HSP90
CA2669054A1 (en) 2006-11-09 2008-05-15 Biotica Technology Limited 18, 21-didesoxymacbecin derivatives for the treatment of cancer
JP2010516282A (ja) 2007-01-26 2010-05-20 コーサン バイオサイエンシーズ， インコーポレイテッド 工学的生合成によるマクロラクタム
US8324240B2 (en) 2007-03-20 2012-12-04 Curis, Inc. Fused amino pyridine as HSP90 inhibitors
GB2449293A (en) 2007-05-17 2008-11-19 Evotec Compounds having Hsp90 inhibitory activity
WO2008151833A2 (en) 2007-06-13 2008-12-18 Hochschule Mannheim Compounds for the modulation of huntingtin aggregation, methods and means for identifying such compounds
IL184671A0 (en) 2007-07-17 2008-12-29 Hadasit Med Res Service Substances directed to heparanase c-terminal domain-or substance derived therefrom and uses thereof as modulators of heparanas biological activities
DE102007041116A1 (de) 2007-08-30 2009-03-05 Merck Patent Gmbh 1,3-Dihydro-isoindolderivate
TW200920357A (en) 2007-09-10 2009-05-16 Curis Inc HSP90 inhibitors containing a zinc binding moiety
EP2060565A1 (en) 2007-11-16 2009-05-20 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
US20110218143A1 (en) 2007-11-20 2011-09-08 University Of Florida Research Foundation Compositions and methods for tissue repair
WO2009084653A1 (ja) 2007-12-28 2009-07-09 Takeda Pharmaceutical Company Limited 細胞保護剤のスクリーニング方法
DK2262778T5 (da) 2008-03-07 2020-06-08 Acraf 1-benzyl-3-hydroxymethylindazolderivativer og brug deraf i behandling af sygdomme baseret på ekspression af mcp-1, cx3cr1 og p40
WO2009114470A2 (en) 2008-03-10 2009-09-17 Curis, Inc. Tetrahydroindole and tetrahdyroindazole as hsp90 inhibitors containing a zinc binding moiety
EP2100879A1 (en) 2008-03-13 2009-09-16 4Sc Ag Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds
GB2474142B (en) 2008-05-19 2012-09-05 Hewlett Packard Development Co Handling passwords for pre-boot log in that cannot be typed with the attached keyboard
EP2313411A1 (en) * 2008-06-10 2011-04-27 Plexxikon, Inc. 5h-pyrr0l0 [2,3-b]pyrazine derivatives for kinase modulation, and indications therefor
WO2010014617A1 (en) 2008-07-28 2010-02-04 University Of Kansas Heat shock protein 90 inhibitor dosing methods
CN102112481A (zh) 2008-08-04 2011-06-29 帝斯曼知识产权资产管理有限公司 使用过氧化氢或过酸由鼠尾草酸生产鼠尾草酚的方法
US20100048482A1 (en) 2008-08-15 2010-02-25 Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating epsilon protein kinase c-mediated cytoprotection
WO2010030395A2 (en) 2008-09-15 2010-03-18 Whitehead Institute For Biomedical Research Withaferin a analogs and uses thereof
PL2370076T3 (pl) 2008-11-28 2017-06-30 Novartis Ag Kombinacja farmaceutyczna zawierająca inhibitor Hsp 90 i inhibitor mTOR
WO2010117425A1 (en) 2009-03-31 2010-10-14 Biogen Idec Ma Inc. Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
CA2786777A1 (en) * 2010-01-07 2011-07-14 Akron Molecules Gmbh Obesity small molecules
US20110201587A1 (en) * 2010-02-16 2011-08-18 Bio Holding, Inc. Hsp90 inhibitors and methods of use
US20120309750A1 (en) 2010-02-17 2012-12-06 Ildong Pharm Co., Ltd. 5-membered heterocycle derivatives and manufacturing process thereof
CA2697887A1 (en) 2010-03-12 2011-09-12 Institut De Recherches Cliniques De Montreal Modulating and/or detecting activation induced deaminase and methods of use thereof
US9062072B2 (en) 2010-04-20 2015-06-23 Emory University Inhibitors of HIF and angiogenesis
WO2012106393A2 (en) 2011-02-01 2012-08-09 University Of Kansas Withanolide isolated from physalis longifolia and analogs and methods of use thereof
WO2012106343A2 (en) 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
US8685966B2 (en) 2011-04-08 2014-04-01 University Of Kansas GRP94 inhibitors
WO2013015661A2 (en) 2011-07-28 2013-01-31 Ildong Pharm Co.,Ltd. Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide
HK1209035A1 (en) * 2012-05-25 2016-03-24 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
CN102772399A (zh) * 2012-08-16 2012-11-14 厦门大学 藤黄酸作为5`-amp激活的蛋白激酶激动剂的用途

Also Published As

Publication number Publication date
WO2013177535A8 (en) 2014-11-13
AU2013266086B2 (en) 2018-03-01
US20170166891A1 (en) 2017-06-15
MX2014014188A (es) 2015-05-11
IL235910A0 (en) 2015-01-29
EP2854865B1 (en) 2019-02-20
US20140154266A1 (en) 2014-06-05
NZ702169A (en) 2016-10-28
EP2854865A4 (en) 2016-03-02
HK1209035A1 (en) 2016-03-24
CN104812898A (zh) 2015-07-29
WO2013177535A3 (en) 2015-03-05
US9533002B2 (en) 2017-01-03
CN104812898B (zh) 2018-01-30
AU2013266086A1 (en) 2014-12-11
JP2015520170A (ja) 2015-07-16
SG11201407775WA (en) 2014-12-30
CA2874676A1 (en) 2013-11-28
WO2013177535A2 (en) 2013-11-28
EP2854865A2 (en) 2015-04-08
KR20150010793A (ko) 2015-01-28
BR112014029301A2 (pt) 2017-07-25
EA201492184A1 (ru) 2015-07-30

Similar Documents

Publication Publication Date Title
JP6478908B2 (ja) 熱ショックタンパク質（ＨＳＰ）９０−βを調節することによる代謝症候群の治療方法
Xie et al. High uric acid induces liver fat accumulation via ROS/JNK/AP-1 signaling
Sasako et al. Hepatic Sdf2l1 controls feeding-induced ER stress and regulates metabolism
Stefanidis et al. The role of thermogenesis in antipsychotic drug‐induced weight gain
Kefaloyianni et al. Proximal tubule–derived amphiregulin amplifies and integrates profibrotic EGF receptor signals in kidney fibrosis
Danilova et al. MANF is required for the postnatal expansion and maintenance of pancreatic β-cell mass in mice
Xu et al. Mitochondrial dysfunction and inhibition of myoblast differentiation in mice with high‐fat‐diet‐induced pre‐diabetes
Shoda et al. Canagliflozin inhibits glioblastoma growth and proliferation by activating AMPK
Saw et al. Activation of the cardiac non-neuronal cholinergic system prevents the development of diabetes-associated cardiovascular complications
Zhao et al. Serum response factor induces endothelial-mesenchymal transition in glomerular endothelial cells to aggravate proteinuria in diabetic nephropathy
Suchacki et al. The serotonin transporter sustains human brown adipose tissue thermogenesis
Hou et al. miR-188-5p silencing improves cerebral ischemia/reperfusion injury by targeting Lin28a
Osaka et al. Luseogliflozin inhibits high glucose-induced TGF-β 2 expression in mouse cardiomyocytes by suppressing NHE-1 activity
Francis et al. Motor end plate innervation loss in diabetes and the role of insulin
Cao et al. ACSL1: A preliminary study that provides a new target for the treatment of renal fibrosis could bring new insights in diabetic kidney disease
Tie et al. CCAAT/enhancer‐binding protein β overexpression alleviates myocardial remodelling by regulating angiotensin‐converting enzyme‐2 expression in diabetes
US20220288071A1 (en) A small molecule therapeutic for parkinson's disease paired with a biomarker of therapeutic activity
US20150018383A1 (en) Biomarkers of renal disorders
Stankovic et al. An update on multiple system atrophy
TWI359271B (en) Pharmaceutical composition for insulin resistance
US10023864B2 (en) Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta
Bai et al. Zyxin—a novel detrimental target, is inhibited by Saikosaponin A during allergic asthma
Pfeuffer et al. Deficiency of the two-pore potassium channel KCNK9 impairs intestinal epithelial cell survival and aggravates dextran sodium sulfate-induced colitis
Lee et al. Regulation of Type 1 Diabetes via Brown Adipocyte–Secreted Proteins and the Novel Glucagon Regulator Nidogen-2
Zhao et al. PDZK1 Protects Against RPE Senescence by Targeting the 14‐3‐3ε‐mTOR Axis to Attenuate Early Diabetic Retinopathy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190205

R150 Certificate of patent or registration of utility model

Ref document number: 6478908

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees